Abstract
The currently available type 1 cysteinyl leukotriene receptor (CysLT1R) antagonists have proven benefits for the treatment of asthma and allergic rhinitis. The type 2 cysteinyl leukotriene receptor (CysLT2R) mediates complex, cell type- or stimulus-specific functions that may either protect from or promote Type 2 immunity in allergic inflammation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
